The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Department of Immunology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China; The Affiliated Huai'an No. 1 People's Hospital, Nanjing Medical University, Huai'an, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Department of Immunology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China; The Affiliated Huai'an No. 1 People's Hospital, Nanjing Medical University, Huai'an, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
Int Immunopharmacol. 2024 Dec 5;142(Pt A):113099. doi: 10.1016/j.intimp.2024.113099. Epub 2024 Sep 12.
Immune checkpoint inhibitor (ICI) has been widely used in the treatment of advanced cancers, but predicting their efficacy remains challenging. Traditional biomarkers are numerous but exhibit heterogeneity within populations. For comprehensively utilizing the ICI-related biomarkers, we aim to conduct multidimensional feature selection and deep learning model construction.
We used statistical and machine learning methods to map features of different levels to next-generation sequencing gene expression. We integrated genes from different sources into the feature input of a deep learning model, by means of self-attention mechanism.
We performed feature selection at the single-cell sequencing level, PD-L1 (CD274) analysis level, tumor mutational burden (TMB)/mismatch repair (MMR) level, and somatic copy number alteration (SCNA) level, obtaining 96 feature genes. Based on the pan-cancer dataset, we trained a multi-task deep learning model. We tested the model in the bladder urothelial carcinoma testing set 1 (AUC = 0.62, n = 298), bladder urothelial carcinoma testing set 2 (AUC = 0.66, n = 89), non-small cell lung cancer testing set (AUC = 0.85, n = 27), and skin cutaneous melanoma testing set (AUC = 0.71, n = 27).
Our study demonstrates the potential of the deep learning model for integrating multidimensional features in predicting the outcome of ICI. Our study also provides a potential methodological case for medical scenarios requiring the integration of multiple levels of features.
免疫检查点抑制剂(ICI)已广泛用于治疗晚期癌症,但预测其疗效仍然具有挑战性。传统的生物标志物很多,但在人群中存在异质性。为了全面利用 ICI 相关生物标志物,我们旨在进行多维特征选择和深度学习模型构建。
我们使用统计和机器学习方法将不同层次的特征映射到下一代测序基因表达。我们通过自注意力机制将来自不同来源的基因整合到深度学习模型的特征输入中。
我们在单细胞测序水平、PD-L1(CD274)分析水平、肿瘤突变负担(TMB)/错配修复(MMR)水平和体细胞拷贝数改变(SCNA)水平进行了特征选择,获得了 96 个特征基因。基于泛癌数据集,我们训练了一个多任务深度学习模型。我们在膀胱癌测试集 1(AUC=0.62,n=298)、膀胱癌测试集 2(AUC=0.66,n=89)、非小细胞肺癌测试集(AUC=0.85,n=27)和皮肤黑色素瘤测试集(AUC=0.71,n=27)中对该模型进行了测试。
我们的研究表明,深度学习模型在整合多维特征预测 ICI 疗效方面具有潜力。我们的研究还为需要整合多个层次特征的医学场景提供了潜在的方法案例。